275 related articles for article (PubMed ID: 24128936)
1. PharmGKB summary: venlafaxine pathway.
Sangkuhl K; Stingl JC; Turpeinen M; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Jan; 24(1):62-72. PubMed ID: 24128936
[No Abstract] [Full Text] [Related]
2. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine.
McAlpine DE; Biernacka JM; Mrazek DA; O'Kane DJ; Stevens SR; Langman LJ; Courson VL; Bhagia J; Moyer TP
Ther Drug Monit; 2011 Feb; 33(1):14-20. PubMed ID: 21099743
[TBL] [Abstract][Full Text] [Related]
3. Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.
Geber C; Ostad Haji E; Schlicht K; Hiemke C; Tadić A
Ther Drug Monit; 2013 Jun; 35(3):279-82. PubMed ID: 23666577
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
5. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.
Vinetti M; Haufroid V; Capron A; Classen JF; Marchandise S; Hantson P
Clin Toxicol (Phila); 2011 Nov; 49(9):865-9. PubMed ID: 22077251
[TBL] [Abstract][Full Text] [Related]
6. Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
Gressier F; Ellul P; Dutech C; Ait Tayeb AEK; Monfort J; Corruble E; Becquemont L; Hardy P; Verstuyft C
Am J Psychiatry; 2014 Aug; 171(8):890. PubMed ID: 25082493
[No Abstract] [Full Text] [Related]
7. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
[TBL] [Abstract][Full Text] [Related]
10. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
Eap CB; Lessard E; Baumann P; Brawand-Amey M; Yessine MA; O'Hara G; Turgeon J
Pharmacogenetics; 2003 Jan; 13(1):39-47. PubMed ID: 12544511
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Henry NL; Stearns V; Flockhart DA; Hayes DF; Riba M
Am J Psychiatry; 2008 Oct; 165(10):1251-5. PubMed ID: 18829880
[No Abstract] [Full Text] [Related]
13. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
[TBL] [Abstract][Full Text] [Related]
14. Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.
Chua EW; Foulds J; Miller AL; Kennedy MA
Pharmacogenet Genomics; 2013 Sep; 23(9):494-7. PubMed ID: 23799451
[TBL] [Abstract][Full Text] [Related]
15. Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.
Nichols AI; Lobello K; Guico-Pabia CJ; Paul J; Preskorn SH
J Clin Psychopharmacol; 2009 Aug; 29(4):383-6. PubMed ID: 19593180
[TBL] [Abstract][Full Text] [Related]
16. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.
Huezo-Diaz P; Perroud N; Spencer EP; Smith R; Sim S; Virding S; Uher R; Gunasinghe C; Gray J; Campbell D; Hauser J; Maier W; Marusic A; Rietschel M; Perez J; Giovannini C; Mors O; Mendlewicz J; McGuffin P; Farmer AE; Ingelman-Sundberg M; Craig IW; Aitchison KJ
J Psychopharmacol; 2012 Mar; 26(3):398-407. PubMed ID: 21926427
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
Augustin BG; Cold JA; Jann MW
Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
[TBL] [Abstract][Full Text] [Related]
20. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]